The absence of a questionable disease in the field of blood tumours, clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a comprehensive assessment platform such as clinical performance, imaging, laboratory testing and pathological activation.
It can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. The individualization of treatment programs for treatment and management factors that are lacking in XI, typically includes drug therapy, rehabilitation interventions, and regular follow-up multi-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of factor XI deficiency. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.